Catalent and Parexel team up to offer clinical trial material supply services

By Natalie Morrison

- Last updated on GMT

Catalent and Parexel form alliance to provide clinical trial material supply services
Catalent and Parexel form alliance to provide clinical trial material supply services
Catalent and Parexel have teamed up to offer clinical trial material supply services.

Under the deal, Parexel will provide clinical logistics services such as global supply chain planning, forecasting and clinical trial material sourcing. Catalent will provide manufacturing, packaging, labelling and analytics services.

The firms say though they have been working together for years, there was demand for a more “formal”​ relationship which integrates the services and covers the full clinical trial life cycle.

“Customers that conduct global clinical trials view global scale and reach as a necessity, they are looking for fewer ‘preferred’ vendors with a broader set of capabilities, and real-time data and system connectivity between the sponsor and the supplier,”​ Catalent’s president of development and clinical services Scott Houlton told

Kurt Norris, corporate VP of clinical logistics for Parexel, added that in the current climate with many biopharma firms suffering the effects of patent expiry there is a need to improve research and development (R&D) productivity and efficiency to make up for revenue losses.

“The alliance directly addresses evolving market dynamics as well as customer needs,” ​he said.

What’s next?

The Parexel deal follows the acquisition of Aptuit​’s clinical trial supplies (CTS) business and is also part of "Catalent’s development and clinical services business growth strategy” ​according to Houlton.

He added that - as part of this growth effort - Catalent will seek more strategic partnerships, particularly in Asia where the firm will “continue to expand our development and clinical supply capabilities.”

As for Parexel, the growing business through the new alliance will be the key focus.

“We will be spending time with our clients discussing further the various benefits stemming from the alliance relative to our end-to-end clinical trial management supply chain solution as well as continuing to execute on those studies for which we are already extending various services,”​ said Norris.

Related news

Show more

Related products

show more

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers